859 related articles for article (PubMed ID: 24572675)
1. Management and outcome of retinoblastoma with vitreous seeds.
Manjandavida FP; Honavar SG; Reddy VA; Khanna R
Ophthalmology; 2014 Feb; 121(2):517-24. PubMed ID: 24572675
[TBL] [Abstract][Full Text] [Related]
2. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.
Gündüz K; Günalp I; Yalçindağ N; Unal E; Taçyildiz N; Erden E; Geyik PO
Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557
[TBL] [Abstract][Full Text] [Related]
3. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma.
Shields CL; Honavar SG; Shields JA; Demirci H; Meadows AT; Naduvilath TJ
Arch Ophthalmol; 2002 Apr; 120(4):460-4. PubMed ID: 11934319
[TBL] [Abstract][Full Text] [Related]
4. Minimal exposure (one or two cycles) of intra-arterial chemotherapy in the management of retinoblastoma.
Shields CL; Kaliki S; Shah SU; Bianciotto CG; Liu D; Jabbour P; Griffin GC; Shields JA
Ophthalmology; 2012 Jan; 119(1):188-92. PubMed ID: 21975042
[TBL] [Abstract][Full Text] [Related]
5. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction.
Demirci H; Eagle RC; Shields CL; Shields JA
Arch Ophthalmol; 2003 Aug; 121(8):1125-31. PubMed ID: 12912690
[TBL] [Abstract][Full Text] [Related]
6. Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma.
Berry JL; Bechtold M; Shah S; Zolfaghari E; Reid M; Jubran R; Kim JW
Ophthalmology; 2017 Dec; 124(12):1817-1825. PubMed ID: 28655537
[TBL] [Abstract][Full Text] [Related]
7. Practical approach to management of retinoblastoma.
Shields CL; Mashayekhi A; Demirci H; Meadows AT; Shields JA
Arch Ophthalmol; 2004 May; 122(5):729-35. PubMed ID: 15136321
[TBL] [Abstract][Full Text] [Related]
8. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma.
Shields CL; Shields JA; Needle M; de Potter P; Kheterpal S; Hamada A; Meadows AT
Ophthalmology; 1997 Dec; 104(12):2101-11. PubMed ID: 9400771
[TBL] [Abstract][Full Text] [Related]
9. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors.
Shields CL; Mashayekhi A; Cater J; Shelil A; Ness S; Meadows AT; Shields JA
Arch Ophthalmol; 2005 Jun; 123(6):765-73. PubMed ID: 15955977
[TBL] [Abstract][Full Text] [Related]
10. Management of advanced retinoblastoma with intravenous chemotherapy then intra-arterial chemotherapy as alternative to enucleation.
Shields CL; Kaliki S; Al-Dahmash S; Rojanaporn D; Leahey A; Griffin G; Jabbour P; Shields JA
Retina; 2013; 33(10):2103-9. PubMed ID: 23873161
[TBL] [Abstract][Full Text] [Related]
11. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation.
Schefler AC; Cicciarelli N; Feuer W; Toledano S; Murray TG
Ophthalmology; 2007 Jan; 114(1):162-9. PubMed ID: 17070578
[TBL] [Abstract][Full Text] [Related]
12. Periocular topotecan for vitreous seeds in retinoblastoma.
Sthapit PR; Rao R; Honavar SG
Indian J Ophthalmol; 2018 Dec; 66(12):1833-1838. PubMed ID: 30451190
[TBL] [Abstract][Full Text] [Related]
13. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes.
Shields CL; Ramasubramanian A; Thangappan A; Hartzell K; Leahey A; Meadows AT; Shields JA
Ophthalmology; 2009 Mar; 116(3):544-551.e1. PubMed ID: 19157557
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results.
Shields CL; Manjandavida FP; Arepalli S; Kaliki S; Lally SE; Shields JA
JAMA Ophthalmol; 2014 Mar; 132(3):319-25. PubMed ID: 24407202
[TBL] [Abstract][Full Text] [Related]
15. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma.
Shields CL; Manjandavida FP; Lally SE; Pieretti G; Arepalli SA; Caywood EH; Jabbour P; Shields JA
Ophthalmology; 2014 Jul; 121(7):1453-60. PubMed ID: 24656794
[TBL] [Abstract][Full Text] [Related]
16. Long-term visual outcome following chemoreduction for retinoblastoma.
Demirci H; Shields CL; Meadows AT; Shields JA
Arch Ophthalmol; 2005 Nov; 123(11):1525-30. PubMed ID: 16286614
[TBL] [Abstract][Full Text] [Related]
17. The International Classification of Retinoblastoma predicts chemoreduction success.
Shields CL; Mashayekhi A; Au AK; Czyz C; Leahey A; Meadows AT; Shields JA
Ophthalmology; 2006 Dec; 113(12):2276-80. PubMed ID: 16996605
[TBL] [Abstract][Full Text] [Related]
18. Chemoreduction for unilateral retinoblastoma.
Shields CL; Honavar SG; Meadows AT; Shields JA; Demirci H; Naduvilath TJ
Arch Ophthalmol; 2002 Dec; 120(12):1653-8. PubMed ID: 12470138
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma.
Zage PE; Reitman AJ; Seshadri R; Weinstein JL; Mets MB; Zeid JL; Greenwald MJ; Strauss LC; Goldman S
Pediatr Blood Cancer; 2008 Mar; 50(3):567-72. PubMed ID: 17729249
[TBL] [Abstract][Full Text] [Related]
20. Combined chemotherapy and local treatment in the management of intraocular retinoblastoma.
Brichard B; De Bruycker JJ; De Potter P; Neven B; Vermylen C; Cornu G
Med Pediatr Oncol; 2002 Jun; 38(6):411-5. PubMed ID: 11984802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
